In a retrospective analysis of 86 newly diagnosed AML patients, these authors showed that a higher proportion of CD34+CD38−CD123+ leukemic stem cells at remission stages was associated with persistent MRD and predicted shorter progression-free survival (PFS) in patients with poor-risk cytogenetics [113]. The gene discussed is CD34; the disease is acute myeloid leukemia.